Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5C | P41229 | 1/20 | 0.61 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | CCR8 | P51685 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19741748 | 0.93 | KDM5C (0.56) | KDM5CKDM4CKDM4EPOLBCYP2D6 | |
| SCHEMBL19741629 | 0.88 | KDM4C (0.57) | KDM5CKDM4CKDM4EPOLBCYP2D6 | |
| SCHEMBL19741688 | 0.87 | KDM5C (0.54) | KDM5CKDM4CKDM4EPOLBCYP2D6 | |
| SCHEMBL19741625 | 0.81 | KDM5C (0.51) | KDM5CKDM4CKDM4EPOLBCYP2D6 | |
| SCHEMBL17144780 | 0.81 | KDM5C (0.51) | KDM5CKDM4CKDM4EPOLBCYP2D6 | |
| SCHEMBL21207165 | 0.79 | KDM4E (0.56) | KDM4EPOLBCYP2D6CYP2C19CCR8 | |
| SCHEMBL15636461 | 0.77 | KDM4C (0.76) | KDM5CKDM4CKDM4ECYP2D6L3MBTL1 | |
| SCHEMBL2305288 | 0.77 | KDM4C (0.76) | KDM5CKDM4CKDM4ECYP2D6L3MBTL1 | |
| SCHEMBL16291774 | 0.76 | KDM4C (0.74) | KDM5CKDM4CKDM4ECYP2D6L3MBTL1 | |
| SCHEMBL28441622 | 0.74 | KDM4C (0.71) | KDM5CKDM4CKDM4ECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369444-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2017-12-28 | — | — | US | claimed |
| US-20170369444-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369444-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM3A, KDM1A | KDM5C 16/4885KDM4C 38/4885KDM4E 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.